04 Nov Questions to Ask Your Provider About Hormone Therapy, From a Menopause-Certified Pharmacist
Medical Notice: Menopausal hormone therapy is a prescription treatment that should only be prescribed and monitored by your healthcare provider. It is not appropriate for everyone, including some people with a history of breast cancer, blood clots, stroke, heart disease, liver disease, or unexplained vaginal bleeding. Compounded hormone products are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality; FDA-approved options, including bioidentical estradiol and progesterone, are available. Seek emergency care for chest pain, shortness of breath, sudden severe headache, vision changes, or leg pain or swelling. This content is for general information only and is not medical advice. Pharmacies, medications and treatment advice named or linked in this post are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.
Navigating hormone therapy for menopause can feel overwhelming, but asking the right questions empowers you to make informed decisions about your health. Whether you're experiencing hot flashes, night sweats, mood changes, or other symptoms, understanding your treatment options is crucial.
This guide walks you through seven essential questions to ask your provider about hormone therapy, designed to help you and your provider create a personalized treatment plan that fits your health profile and goals.
Dr. Pollard[/caption]
Michael S. Pollard, Ph.D.
Professor, Pardee RAND Graduate School
Senior Sociologist
RAND Corporation
Santa Monica, CA 90407-2138
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: There are ample anecdotal jokes and stories about increased alcohol use during COVID-19 and stay-at-home orders. Our study provides robust longitudinal evidence that people drank more frequently, and for women in particular, more heavily, and with more negative consequences, during the initial stages of COVID-19 compared to their own behaviors from a year earlier (May/June 2020 compared to May/June 2019). Women’s alcohol consumption was most significantly changed, with a 17% increase in number of days drinking, and a 41% increase in days of binge drinking (when they had four or more drinks in a couple of hours). This means that, nationally, one in five women drank heavily one more day a month than the same time in 2019, on average. Women also reported a 39% increase in alcohol-related problems, such as “I took foolish risks” or “I failed to do what was expected of me” because of drinking alcohol.
Dr. Al-Hendy[/caption]
MedicalResearch.com: What is the background for this approval?
Uterine fibroids, commonly referred to as uterine leiomyomas, are the most common type of non-cancerous tumor known to impact women of reproductive age (30-50 years old). In fact, studies show that uterine fibroids can occur in up to 70 percent of European American women and over 80 percent of African American women by age 50. As a result of uterine fibroids, women can experience a range of symptoms, the most common being heavy menstrual bleeding (i.e. prolonged and/or frequent bleeding), which can lead to other health effects such as anemia, fatigue, pelvic pain, urinary frequency etc.
Uterine fibroid treatment recommendations have historically been based on the size and location of the fibroid(s). When treating larger and more complicated fibroids, healthcare providers have typically believed that surgery is their best course of action, which has made uterine fibroids the leading reason for the hysterectomies performed in the U.S. The FDA approval of ORIAHNN was based on improving care for uterine fibroid sufferers who have had a negative impact on their quality of life due to disruptive symptoms. What makes the approval of ORIAHNN so exciting, is that women now have an oral therapy to directly address heavy menstrual bleeding due to uterine fibroids.
Marco Taglietti, M.D.
President and Chief Executive Officer
SCYNEXIS Inc
Dr. Taglietti discusses SCYNEXIS’ announcement of positive results from its second Phase 3 study investigating the safety and efficacy of oral ibrexafungerp as a treatment for vaginal yeast infection.
[caption id="attachment_54239" align="alignleft" width="200"]





